All data are based on the daily closing price as of April 22, 2025
a

Astellas Pharma

4503.TSE
9.61 USD
0.11
+1.16%

Overview

Last close
9.61 usd
Market cap
17.20B usd
52 week high
12.40 usd
52 week low
8.65 usd
Target price
13.34 usd

Valuation

P/E
N/A
Forward P/E
12.3457
Price/Sales
1.2925
Price/Book Value
1.6208
Enterprise Value
22.25B usd
EV/Revenue
1.6728
EV/EBITDA
22.3042

Key financials

Revenue TTM
13.30B usd
Gross Profit TTM
10.84B usd
EBITDA TTM
2.85B usd
Earnings per Share
-0.23 usd
Dividend
0.51 usd
Total assets
22.08B usd
Net debt
4.71B usd

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.
  • Symbol
    4503.TSE
  • Exchange
    TSE
  • Isin
    JP3942400007
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Naoki Okamura BSc
  • Headquarter
    Tokyo
  • Web site
    https://www.astellas.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top